Search
Fenpropidin
go.drugbank.com/drugs/DB12728ApprovedWithdrawnFenpropidin has been investigated for the treatment of Hernia.
Alclometasone
go.drugbank.com/drugs/DB00240ApprovedAlclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.
Lithium hydroxide
go.drugbank.com/drugs/DB14506ApprovedWithdrawnUsed for tryptophan determinations in proteins & foods.
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] It is used to identify tau NFT pathology in adults with cognitive impairment being evaluated for Alzheimer's disease and has not been established for evaluating non-Alzheimer's tauopathies. … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease
Moricizine
go.drugbank.com/drugs/DB00680ApprovedWithdrawnAn antiarrhythmia agent used primarily for ventricular rhythm disturbances.
Liotrix
go.drugbank.com/drugs/DB01583ApprovedAdministration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage.
Ticlopidine
go.drugbank.com/drugs/DB00208ApprovedTiclopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.
Ifenprodil
go.drugbank.com/drugs/DB08954ApprovedInvestigationalWithdrawn[A196128] Ifenprodil is being investigated for its potential utility in treating COVID-19 in an ongoing phase 2b/3 clinical trial (NCT04382924).[L16343] … Binding at the LBD of the agonists glycine (or D-serine) to the GluN1 subunits and of glutamate to the GluN2 subunits is a regulatory mechanism for channel activation.
Categories: Experimental Unapproved Treatments for COVID-19